Jesse Dovich, MD, Wins Tesla at 2017 ASCRS Meeting

May 8, 2017: By Market Scope
Jesse Dovich, MD (right), winner of the Tesla at the 2017 ASCRS meeting.

Jesse Dovich, MD (right), winner of the Tesla at the 2017 ASCRS meeting. (Photo by Katie Cannady)

 

Ophthalmologist Jesse Dovich, MD, of Upland, California, was the winner of this year’s drawing for a Tesla electric car at the ASCRS annual meeting in Los Angeles.

The drawing was held May 8 at the ASCRS Exhibit Hall.

Dovich won a 2017 sapphire blue Model S.

He practices at the Pacific Eye Institute and Laser Center, with several locations in California, and is a clinical instructor with the Department of Ophthalmology at Loma Linda University.

In 2015, Thomas Carter, MD, of Ponca City, OK, won the ASCRS’ initial drawing for a 2015 red Tesla Model S at the meeting in San Diego.

In 2016, David Russell Brear, MD, of Culpeper, VA, was the winner of a blue Tesla Model S at the annual meeting in New Orleans.

This year’s drawing was available to conference attendees who obtained specially numbered tickets from exhibitors or ASCRS officials.

Attendees also could gain a ticket by contributing to the ASCRS Foundation or completing the ASCRS clinical survey.

Dovich’s ticket was the first one drawn.

 

A crowd forms May 8 at the Exhibit Hall for the drawing of a Tesla Model S at the 2017 ASCRS meeting in Los Angeles.

A crowd forms May 8 at the Exhibit Hall for the drawing of a Tesla Model S at the 2017 ASCRS meeting in Los Angeles. (Photo by Tony Ingenito)

 

Tesla winner Jesse Dovich after the drawing

Tesla winner Jesse Dovich, MD, after the drawing. (Photo by Katie Cannady)

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Eylea Gains Approval in China for DME-Related Visual Impairment

Second Trial for Ophthalmic Industry Leader James Mazzo Ends in Hung Jury, Mistrial

Melgen Receives 17-Year Sentence for Medicare Fraud

NIH’s National Eye Institute Solicits Next-Generation Retina Organoids in $1 Million Prize Competition

Taiwan Liposome Company Registers for $50 Million IPO in US

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023